Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Placebo-controlled Dose Modification Study to Evaluate the Safety and Efficacy of Single Doses of Vanoxerine for Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm

NCT01691313 is registered in ClinicalTrials.gov with Laguna Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01691313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01691313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Placebo-controlled Dose Modification Study to Evaluate the Safety and Efficacy of Single Doses of Vanoxerine for Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm
Lead sponsor
Laguna Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2012
Completion date
October 31, 2013
Enrollment
104 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

atrial flutter, symptomatic atrial fibrillation